PLC Systems Inc. announced that it has entered into exclusive agreement with Medimen (Pvt.) Ltd. for three years to distribute RenalGuard System into Bangladesh and Pakistan. Medimem has launched RenalGuard in Bangladesh and will targeting early adopters in both countries. The unique fluid balancing capabilities of RenalGuard will be beneficial in a cath lab setting during cardiovascular imaging procedures for patients at higher risk of Contrast-Induced Nephropathy (CIN).
PLC’s President and Chief Executive Officer, Mark R. Tauscher, said, We are very pleased to extend the launch of our RenalGuard technology to another region of the world, working with our partners at Medimen. We believe Medimen’s efforts will help raise awareness of the benefits of RenalGuard to a wider community of physicians in both Bangladesh and Pakistan.
PLC has launched the RenalGuard in Bangladesh, Pakistan, Italy and Spain till date. In late December 2007 PLC received CE mark for RenalGuard system and the pilot safety trial in the US was concluded in late 2007. Two investigator-sponsored randomized clinical trials in Italy are still underway to evaluate the use of RenalGuard in the prevention of CIN. The company also received patent in Canada for RenalGuard technology.